Cargando…

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study

Detalles Bibliográficos
Autores principales:	Le Moal, G, Beraud, G, Prazuck, T, Hocqueloux, L, Dupuis, A, Venisse, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113049/ http://dx.doi.org/10.1186/1758-2652-13-S4-P46

Ejemplares similares

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
por: Hocqueloux, Laurent, et al.
Publicado: (2012)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
por: Baudry, T, et al.
Publicado: (2010)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
por: Siccardi, M, et al.
Publicado: (2010)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
por: Eche, Simeon, et al.
Publicado: (2021)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
por: Mishra, Tulsidas, et al.
Publicado: (2014)

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
por: Fenley, Juliana de C., et al.
Publicado: (2022)

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study
por: Meijide, Héctor, et al.
Publicado: (2010)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
por: Garvey, LJ, et al.
Publicado: (2010)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
por: Smith, Christiana, et al.
Publicado: (2016)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2022)

Administration of darunavir tablets in patients with difficulties in swallowing – two case reports
por: Scholten, S, et al.
Publicado: (2010)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs
por: Muya, Esther, et al.
Publicado: (2019)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e7t368ngt64c441a5vu0hpfa70